Funding
Series B · Biotech

Galux raises $29m Series B for protein-design platform

Yuanta Investment, Korea Development Bank and other investors participated in the financing.

Updated Oct 16, 2026By RoundOS Funding desk

Galux raised $29 million in Series B financing on February 9. Participants included Yuanta Investment, Korea Development Bank, InterVest, DAYLI Partners, Pathway Investment, SL Investment, NCORE Ventures, SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities. The company uses AI-driven protein design for de novo antibody and drug discovery.

Funding history

Series B · This round$29M

Sources

  1. Galuxprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related